Mint Tower Capital Management B.V. Purchases Shares of 250,000 Drugs Made In America Acquisition II Corp. $DMII

Mint Tower Capital Management B.V. acquired a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 250,000 shares of the company’s stock, valued at approximately $2,475,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC bought a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $265,000. ABC Arbitrage SA bought a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $396,000. Deltec Asset Management LLC bought a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $495,000. Periscope Capital Inc. bought a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $2,628,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $3,960,000.

Analyst Upgrades and Downgrades

DMII has been the subject of several recent research reports. Weiss Ratings reissued a “sell (e)” rating on shares of Drugs Made In America Acquisition II in a research report on Friday, May 29th. Wall Street Zen raised shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Drugs Made In America Acquisition II currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Trading Down 0.0%

Drugs Made In America Acquisition II stock opened at $10.09 on Friday. Drugs Made In America Acquisition II Corp. has a 52 week low of $9.86 and a 52 week high of $10.09. The business’s 50 day moving average price is $10.03.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.